cancer (6, 7) . Afterwards, a polymeric micelle formulation of PCT, Genexol-PM, and a liposome formulation, Lipusu, were commercialized in Korea and China, respectively. These formulations provide the PCT solubility without using toxic solvents, while they decrease the toxic side effects and improve the drug's therapeutic efficacy by a better drug distribution (8) (9) (10) (11) . The phase III clinical trials of a polymeric conjugate of PCT with a water-soluble polymer polyglutamic acid, Opaxio (paclitaxel poliglumex; formerly called Xyotax), is ongoing. The preclinical studies revealed that Opaxio can more effectively target PCT to the tumorous tissue compared to standard PCT. This is explained by the leakage of PCT conjugate through leaky tumor vessels and its entrapment in the tumor site. The proteinic polymer is metabolized inside the tumor cell and then releases PCT (12) . Other PCT delivery systems such as solid lipid nanoparticles, nanoparticles of biodegradable polymers, micellar nanocarriers, nanohydrogels, and dendrimers have also been intensively investigated (1, (13) (14) (15) (16) (17) (18) (19) .
In aqueous mediums, nonionic surfactants are known to form niosomes, which are closed, bilayered structures that vary in size from a few hundred nanometers to several micrometers (20) . Depending on the preparation technique, niosomes can be in small unilayered or multilayered forms. The hydrophilic head groups of the nonionic surfactants are placed in the outer and inside part of the vesicle, and the hydrophobic groups face each other inside the bilayer (Figure 1 ). Thus, while the hydrophilic active agents are entrapped inside the vesicle, the hydrophobic agents are entrapped inside the bilayers (21, 22) . The first niosome formulation was developed in 1975 and was patented as an antiaging cosmetic product by L'Oréal. Afterwards, the studies for the usage of niosomes as drug delivery systems started.
In a previous study, PCT-carrying niosomes were prepared with various surfactant types (Tween 20 and 60; Span 20, 40 , and 60; Brij 76, 78, and 72) by using the thin-film technique. The in vitro characterization studies on these formulations revealed the formation of nanosized niosomes with varying surface charges between -40 and -53 mV. The Span 20, 40, and 60 and Brij 72 surfactants, which have low hydrophile-lipophile balance values, were found to be more appropriate for the entrapment of PCT in niosomes (5) . Among these formulations, the niosomes prepared with Span 40 were further evaluated using differential scanning calorimetry and X-ray diffractometry to observe the interaction between PCT and other formulation excipients. The outcomes showed that PCT was in an amorphous form inside the niosomes; the highly lipophilic active agent was loaded inside the bilayer lipid membrane by partition and thus provided slow in vitro PCT release (23) .
The purpose of the present work was to investigate the pharmacokinetic behavior and distribution of PCT in the tissues from the PCT-loaded Span 40 niosomes compared to a commercially available i.v. preparation, Taxol, each administered intravenously to rats.
Materials and methods

Materials
PCT, cholesterol, and dicetyl phosphate (DCP) were purchased from Sigma-Aldrich (Milwaukee, WI, USA). Docetaxel and Span 40 (sorbitan monopalmitate) were bought from Fluka (Buchs, Switzerland). Acetonitrile, chloroform, methanol, and t-butyl methyl ether were purchased from Merck (Darmstadt, Germany). Sodium chloride was bought from Carlo Erba (Milan, Italy). Milli-Q water was used in the experiments (Millipore, MA, USA). Taxol (Bristol Mayer Squibb Inc., İstanbul, Turkey; Lot No. 8C46893) was purchased from a pharmacy (Ankara, Turkey).
PCT formulations
Niosomes were prepared using the thin-film method (5 Both formulations were diluted to 1 mL with ultrapure water in order to have the required doses of the drug (2.5 mg/kg) and were injected to the rats' femoral veins. Blood samples of 200 µL were collected from the tail veins of the rats at the time points of 0.05, 0.25, 0.5, 1, 2, 4, 6, 10, and 24 h into ice cold heparinized test tubes. Plasma was separated from blood samples by centrifugation at 10,000 rpm for 10 min and stored at -60 °C until drug analysis.
After collecting blood samples from rats at h 24, the rats were anesthetized with ether and sacrificed via exsanguination. The liver, spleen, lungs, heart, and intestines were excised and rinsed thoroughly with saline 3 times. Tissue samples were blot-dried, weighed, and stored at -60 °C until drug analysis.
HPLC analysis of PCT in plasma and tissue samples
Standard solutions of PCT were prepared in acetonitrile at different concentrations. After gentle thawing, blank plasma samples (100 µL) were spiked with 25 µL of PCT solutions, 10 µL of internal standard (docetaxel 15 µg/ mL), and 50 µL of methanol, and then 1 mL of t-butyl methyl ether was added. The mixtures were centrifuged at 15,000 rpm, and 1 mL of supernatant from each of them was taken into a test tube. After evaporation of the organic solvent at 40 °C, the residue was dissolved in 100 µL of methanol and was injected in the column of HPLC system (Agilent 1100, Waldborn, Germany). The chromatographic separation was achieved on a Waters Symmetry C18 reverse-phase column (150 mm × 4.6 mm, 5 µm) at 25 °C. The mobile phase was a mixture of acetonitrile (with 0.1% formic acid, v/v) and water (46:54, v/v). The UV detection was performed at a wavelength of 195 nm, the flow rate was 1.0 mL/min, and the injection volume was 25 µL. The calibration curve was constructed by plotting PCT concentrations versus the peak area ratios of PCT to docetaxel (24) . PCT was extracted from the blood and tissue samples according to the procedure given in Figure 2 . The extracts were analyzed by HPLC, and the drug concentrations were calculated from the obtained calibration curve.
Method validation
The method was validated in terms of accuracy, precision, reproducibility, repeatability, intermediate precision, specificity, linearity, and limit of detection and quantification according to ICH and FDA guidelines for the bioanalytical method validation (25, 26) . The pharmacokinetic parameters were calculated by Kinetika ver. 5.0 (Thermo Fisher Scientific, Waltham, MA, USA) using a noncompartmental method. The maximum plasma concentration (C max ) was directly obtained from plasma concentration-time graphs. The parametric statistical evaluation of the data was performed through one-way variance analysis followed by Tukey multiple comparisons employing SPSS 9.0 for Windows (SPSS Inc., Chicago, IL, USA). 
Calculation and statistical analysis
Results
Quantitative analysis of PCT in biological samples and method validation
The HPLC method was described in our previous studies (5, 24) . The method was fully validated and used for the determination of PCT in blood and tissue samples after i.v. administration to the rats. In HPLC methods, accuracy and precision can often be improved by using an internal standard. An internal standard compensates for the potential changes in the sample size or concentration originating from instrumental variations by correcting fluctuations in detector response (27) . Docetaxel (DCT) was used as an internal standard in this study. Samples were prepared by spiking the rat plasma with known concentrations of PCT and DCT and then extracting the drug according to the procedure given in Figure 2 . The retention times were 11.5 min for PCT and 9.91 min for DCT ( Figure 3 ). The calibration curve obtained by plotting the peak area ratio of PCT to DCT versus PCT concentrations became linear over the range of 0.04-0.60 µg/mL with the determination coefficient (r 2 ) of 0.9905. The limits of quantification and detection were 16.18 × 10 -3 µg/mL and 5.34 × 10 -3 µg/mL, respectively. The accuracy of a method describes the proximity of mean test results to the true concentrations, while precision describes the proximity of each measurement result obtained from the procedure, which is repeatedly applied to the biological samples. The accuracy and precision by repeatability were indicated by performing 6 measurements on each of 3 different concentrations of PCT (low: 0.1 µg/mL, medium: 0.2 µg/mL, and high: 0.5 µg/ mL), prepared by spiking the solutions into the rat plasma and calculating the concentrations by the calibration curve of the drug. Furthermore, the precision was also determined using intermediate precision. The intermediate precision is established depending on the variations, such as different days and analysts, to see the effects of random events on the precision of the analytical procedure (25) . Three different concentrations of PCT (low, medium, and high) in rat plasma were prepared, and each of them was measured 6 times by HPLC on different days (1st, 2nd, and 3rd days) by the same analyst. Relative standard deviations of these determinations were quite low at the level of 2%, showing adherence to the FDA guideline (26) . Blank samples of rat plasma and tissues as a biological matrix and the solvents that were used in the analytical method were handled the same as in the extraction procedure in Figure 2 and analyzed by HPLC. The peaks from the blank samples did not interfere with those of the samples containing PCT and DCT, demonstrating the selectivity of the analytical method. Figure 4 shows the measured plasma concentrations of PCT versus time after i.v. administration of the niosome formulation and of the commercially available i.v. preparation, Taxol, given to the rats in a single dose of 2.5 mg/kg The plasma concentrations of PCT obtained within the first 2 h after drug administration were similar in both administration groups, as seen in the inset of Figure 4 . Then a fast decline in PCT plasma concentration occurred in the rats administered Taxol, with the final PCT measurement occurring after 6 h. On the other hand, the PCT plasma curve of the rats administered PCT-loaded Span 40 niosomes formed a plateau at an almost steadystate concentration starting at 2 h and lasting until 24 h.
Pharmacokinetic and tissue distribution studies
The pharmacokinetic parameters calculated from the plasma concentrations vs. time curves are given in the Table. The maximum plasma concentrations (C max values) were 0.754 ± 0.123 µg/mL and 0.872 ± 0.187 µg/mL for Taxol and the niosomes, respectively. The difference between the C max values was not statistically significant (P > 0.05). The value of area under the curve, AUC 0-24 , was 0.725 ± 0.163 µg h/mL in the group that received Taxol. When this value is compared to the AUC 0-24 value of the group that received niosomes (3.22 ± 0.255 µg h/mL), the niosomes were found to be significantly more effective for enhancing the bioavailability of PCT (P < 0.001). In the rat group that received Taxol, the mean residence time (MRT) and the elimination half-life (T 1/2 ) of PCT were estimated as 1.66 ± 0.133 h and 1.15 ± 0.085 h, respectively. The MRT and T 1/2 values of PCT were 11.0 ± 0.6 h and 7.63 ± 0.380 h, respectively, in the rat group that received niosomes. There were statistically significant differences between these values (P < 0.001). The general excretion rate of drug Plasma concentrat on ( g/mL) µ from plasma, the L z value, determined from the Taxoladministered group was found to be significantly higher (0.624 ± 0.0532 h -1
) than the value determined from the niosome-administered group (0.0925 ± 0.00490 h -1 ) (P < 0.001).
The tissue distribution of PCT in the liver, intestines, kidneys, heart, lungs, and spleen after i.v. administration of Taxol and Span 40 niosomes to the rats at 24 h is shown in Figure 5 . The concentrations of PCT in the Taxol group seem to be higher in all tissues in comparison to the niosome group, and the values calculated for liver (P < 0.05), heart (P < 0.05), and kidneys (P < 0.10) were statistically significantly different. The accumulation of PCT was substantially high in the spleen compared to the other tissues after both niosome and Taxol administration.
Discussion
Liposomes have been widely studied as drug delivery systems in the vesicular system, and there are currently numerous liposome preparations on drug market (28) . However, some hurdles have been faced in regard to the pharmaceutical development of these systems. These obstacles include the poor quality of the phospholipids used for the preparation of liposomes, their expensiveness, chemical stability problems such as hydrolysis and oxidation that lead to too-short shelf life, and scaleup problems. Due to these issues, niosomes have been presented as an alternative system (21, 29) .
Niosomes behave similarly to liposomes in vivo. Besides the general advantages of drug delivery systems, they have distinct advantages such as control of shape, size, composition, and fluidity when required; biodegradability, biocompatibility, and nonimmunogenicity to the body; targeting drugs to various organs; sustained drug release; entrapment of both hydrophilic and hydrophobic drugs; easy handling and storage conditions; suitability for industrial manufacture due to relatively low cost of materials; and sterilization by membrane filtration, autoclaving, and gamma irradiation (21, 30) .
Concerning the advantages of the niosomal drug delivery systems, our objective was to develop an alternative formulation that could overcome the poor aqueous solubility of PCT and avoid the use of Cremophor EL, which causes serious adverse effects in the clinical application of Taxol. Different classes of nonionic surfactants have been used for the preparation of niosomes. The diversity of the surfactants offers a chance to design the niosomes to meet our expectations. The selection of the surfactants highly depends on the in vitro performance and qualities of the niosomes, such as drug-loading efficiency, particle size, and drug release (5, 23, 24) . In this report, PCTloaded niosomes were prepared with the most appropriate surfactant, Span 40, that we had previously determined with in vitro studies. The pharmacokinetic parameters and tissue distribution of PCT upon i.v. administration were investigated by comparing these values with Taxol administration.
The HPLC method, which was used to measure PCT in plasma and tissue samples, was validated. The linearity range covered the studied concentrations, and PCT was separated from the endogenous components without any interference (Figure 3 ). Figure 4 shows the mean plasma concentrations of PCT against time, measured after i.v. administration of niosomes and Taxol. The early time points on the graph show that the decrease in PCT concentration was fast for both preparations initially, and at later time points the decrease slowed down for the niosomes. The first part of the graph covers the distribution phase of the PCT from the plasma to the tissues, which also includes elimination. After attaining steady-state concentrations between plasma and tissue, PCT concentrations decrease only by elimination. Upon oral administration of the same niosome formulation, a similar plasma concentration-time profile was obtained following the PCT absorption stage (24) . Pharmacokinetic parameters of PCT from the niosome formulation were significantly better than the results from the Taxol group (Table) . The AUC value of PCT from the group administered niosomes was 4.44 times higher compared to the group administered Taxol. The MRT value of PCT is 11 h, and it was 6.6 times higher than that of Taxol. Similarly, the PCT elimination half-life T 1/2 value after the niosome application was 6.6 times higher than the half-life of Taxol. Therefore, the coefficient of general excretion of the drug was 6.7 times lower than in the Taxol group.
The long blood-circulation time of the niosomes was related to the small particle size of the niosomes, which was 133 ± 6 nm. On the other hand, the size of the micelles formed upon dilution of Taxol with water was 13.08 ± 0.0415 nm. The literature data show that nanoparticles with small sizes (40-300 nm or 200 nm) have the ability to escape from the reticuloendothelial system and thus exhibit a slower clearance rate (31). The importance of particle size is very well known for sustained drug release and targeted delivery of drugs. Tumor cells display leaky blood vessels and poor lymphatic drainage. While unattached drugs may distribute nonspecifically into the body, nanocarriers can accumulate specifically into the tumor tissue through the enhanced permeability effect of the tumor vasculature (32, 33) . The prolonged circulation time and the small particle size of PCT-loaded Span 40 niosomes demonstrated the potential of niosomes for the passive targeting of cancer cells. This situation can be further elucidated with in vivo experiments on tumorbearing animals. The long blood-residence time also demonstrated the niosome stability. The stability of a nanocarrier is important for its eventual accumulation in the tumor tissue (31) . Similar pharmacokinetic behavior was observed upon i.v. administration of PCT-loaded pegylated polymeric micelles as another nanoparticulate drug-delivery system. The investigators compared the results with a commercially injectable PCT product and observed higher AUC, longer systemic circulation times, and slower plasma elimination rates upon administration of micellar formulation. Therefore, they suggested the usage of polymeric micelles due to their long-circulating property.
One of the major limitations of cancer therapy is the nonspecific systemic distribution of anticancer agents, which can lead to severe side effects in sensitive healthy tissues. Therefore, tissue distribution studies on the vital organs were conducted (16, 34) . Figure 5 shows tissue distribution of PCT after i.v. administration of Taxol and PCT-loaded niosomes at the end of 24 h. In the Taxoladministered rat group, PCT was distributed widely to all of the examined tissues, although it could not be detected in plasma beyond 6 h after administration. However, PCT-loaded Span 40 niosomes clearly altered the tissue distribution of PCT in rats. The accumulated amounts of PCT in the liver, kidneys, and heart were significantly reduced in the niosome-administered group. This result emphasized the selective tissue distribution of the niosomes. Additionally, lower accumulation of PCT in the heart and kidneys might be an important piece of evidence in terms of the prevention of cardiotoxicity and nephrotoxicity observed during chemotherapy. The spleen accumulations of the drug were higher than in the other tissues in both PCT formulations. This result reveals that PCT is filtered by the spleen during the circulation in the blood and suggests the potential usage of niosomes for specific drug delivery to the spleen.
There are several studies in which niosomes were evaluated as drug carrier systems for anticancer agents such as hydroxycamptothecin (HCPT), doxorubicin, methotrexate, 5-fluorouracil, cisplatin, and pentoxifylline (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) . The results obtained in the present study agree well with those of the previous studies. The pharmacokinetics and tissue distribution of anticancer agent HCPT-loaded Span 60 niosomes, pegylated niosomes, and an active targeting agent, transferrin-bound pegylated niosomes, were investigated following their i.v. administration in tumor-bearing mice in a model compared with a plain drug solution. In the group given the HCPT solution, the HCPT was removed very rapidly from the blood circulation. The plasma levels of HCPT for the Span 60 niosomes remained high for the longest time, followed by pegylated niosomes and, finally, transferrin-pegylated niosomes. The tissue distribution of HCPT from the niosome preparations showed the highest concentration in the spleen and tumor tissues. The liver, lungs, kidneys, heart, and brain were in the same rank for niosomes; the lowest accumulation values were observed for the HCPT solution (36) . In another study, doxorubicin as a polymeric conjugate was entrapped in niosomes prepared with hexadecyl diglycerol ether surfactant and polyethylene glycol compound Solulan C24. The plasma clearance of the polymeric conjugate-loaded niosomes with a mean size of 420 nm was rapid, and the niosomes were uptaken mainly by the liver and spleen of the reticuloendothelial system. The rapid plasma clearance was different in the present study, and this might be ascribed to the different composition and larger particle size of the niosomes. However, the sustained release of the free drug in the liver by the niosomes proposes the usefulness of niosomecontaining prodrugs in the treatment of liver-related diseases (37) .
In this study, PCT-loaded Span 40 niosomes with a mean size of 133 nm were prepared by thin-film method. A simple, sensitive HPLC method was developed and validated for the determination of PCT from Span 40 niosomes in rat plasma and tissues. The niosomes increased the AUC value of PCT by 4.44-fold compared to the commercial preparation of PCT, Taxol. Likewise, when this result was compared with the previous results obtained upon oral administration of the niosomes, there was an 8.09 times improvement in AUC values (24) . The prolonged detection of PCT in plasma revealed the slow release of the drug from niosomes. According to the tissue distribution study, niosomes were removed from the blood by the spleen and the amounts of PCT from niosomes in the liver, kidneys, and heart were significantly lower than those obtained from Taxol. These results provide strong support for the targeting of niosomes to tumor tissues and the reduction of side effects to healthy tissues. Further evaluations of niosomes in tumor-bearing mice have been planned and will be beneficial for the demonstration of passive tumor targeting ability of PCT-loaded niosomes.
